Authors
J Kevin Baird, Melva Louisa, Rintis Noviyanti, Lenny Ekawati, Iqbal Elyazar, Decy Subekti, Krisin Chand, Anggi Gayatri, Instiaty Instiaty, Saraswati Soebianto, Chelzie Crenna-Darusallam, Dwi Djoko, Bambang Dwi Hasto, Dubel Meriyenes, David Wesche, Erni J Nelwan, Inge Sutanto, Herawati Sudoyo, Rianto Setiabudy
Publication date
2018/8/3
Journal
JAMA Network Open
Volume
1
Issue
4
Pages
e181449-e181449
Publisher
American Medical Association
Description
Importance
Latent hepaticPlasmodium vivaxhypnozoites provoke repeated clinical attacks called relapses. Only primaquine phosphate kills hypnozoites, and its therapeutic activity may depend on naturally polymorphic cytochrome P450 2D6 isotype (CYP2D6) activity.
Objective
To examine the association of impairedCYP2D6genotypes and CYP2D6 metabolic phenotypes with therapeutic failure of directly observed high-dose primaquine treatment forP vivaxmalaria relapse.
Design, Setting, and Participants
Nested case-control study of patients who, in July 2014, completed a randomized clinical trial of directly observed primaquine treatment for radical cure of acuteP vivaxmalaria in an area of Indonesia where reinfection during 1 year of posttreatment follow-up was improbable. A total of 177 of 180 patients withP vivaxmalaria completed the clinical trial of primaquine treatment to prevent relapse; 151 were eligible for …
Scholar articles
JK Baird, M Louisa, R Noviyanti, L Ekawati, I Elyazar… - JAMA Network Open, 2018